PMID- 24167945
OWN - NLM
STAT- MEDLINE
DCOM- 20131205
LR  - 20141120
IS  - 0033-2240 (Print)
IS  - 0033-2240 (Linking)
VI  - 70
IP  - 7
DP  - 2013
TI  - [Homocysteine and its role in pathogenesis of Parkinson's disease and other 
      neurodegenerative disorders].
PG  - 443-7
AB  - Homocysteine (Hcy) has recently become the focus of interest in the research on 
      Parkinson's disease (PD) and other neurodegenarative disorders. Chronic treatment 
      with levodopa (LD), considered the standard treatment for PD, leads to an 
      increase in homocysteine concentration in serum and cerebro-spinal fluid. 
      Independently from this effect, homocysteine is also regarded as a marker of 
      neurodegenerative disorders. Main interest was focused on hyperhomocysteinemia 
      (hHcy) as the potential risk factor for atheromatosis. Subsequently, its role in 
      neuropsychiatric diseases, e.g. depression, mild cognitive impairment and 
      dementia was investigated. The potential pathogenic role of Hcy in peripheral 
      neuropathy in patients with PD that are treated with LD is an interesting 
      hypothesis but the literature is scarce. Confirmation of this association may 
      lead to introduction of preventive therapies, e.g. administration of vitamin B 
      and inhibitors of catechol-O-methyl transferase (COMT) that may decrease the Hcy 
      blood concentrations.
FAU - Szadejko, Karol
AU  - Szadejko K
AD  - Oddzial Neurologii, 7 Szpital Marynarki Wojennej w Gdansku-Oliwie. 
      kmottkarol@hotmail.com
FAU - Szabat, Krzysztof
AU  - Szabat K
FAU - Ludwichowska, Anna
AU  - Ludwichowska A
FAU - Slawek, Jaroslaw
AU  - Slawek J
LA  - pol
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Rola homocysteiny w patogenezie choroby Parkinsona i innych schorzen 
      neurozwyrodnieniowych.
PL  - Poland
TA  - Przegl Lek
JT  - Przeglad lekarski
JID - 19840720R
RN  - 0 (Catechol O-Methyltransferase Inhibitors)
RN  - 0LVT1QZ0BA (Homocysteine)
RN  - 12001-76-2 (Vitamin B Complex)
RN  - 46627O600J (Levodopa)
SB  - IM
MH  - Catechol O-Methyltransferase Inhibitors
MH  - Homocysteine/*blood/cerebrospinal fluid
MH  - Humans
MH  - Hyperhomocysteinemia/blood/*chemically induced/*prevention & control
MH  - Levodopa/*adverse effects/*pharmacology
MH  - Neurodegenerative Diseases/blood
MH  - Parkinson Disease/*blood/cerebrospinal fluid/*drug therapy
MH  - Vitamin B Complex/therapeutic use
EDAT- 2013/10/31 06:00
MHDA- 2013/12/16 06:00
CRDT- 2013/10/31 06:00
PHST- 2013/10/31 06:00 [entrez]
PHST- 2013/10/31 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
PST - ppublish
SO  - Przegl Lek. 2013;70(7):443-7.